CA3136369A1 - Compounds and methods for the treatment of ocular disorders - Google Patents

Compounds and methods for the treatment of ocular disorders Download PDF

Info

Publication number
CA3136369A1
CA3136369A1 CA3136369A CA3136369A CA3136369A1 CA 3136369 A1 CA3136369 A1 CA 3136369A1 CA 3136369 A CA3136369 A CA 3136369A CA 3136369 A CA3136369 A CA 3136369A CA 3136369 A1 CA3136369 A1 CA 3136369A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
optionally substituted
heteroalkyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136369A
Other languages
English (en)
French (fr)
Inventor
Ian Holmes
Yair Alster
Hila Barash
Charles Bosworth
Omer Rafaeli
Marc GLEESON
Mark Richard Stewart
Jonathan DUNN
Robert M. Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azura Ophthalmics Ltd
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of CA3136369A1 publication Critical patent/CA3136369A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3136369A 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders Pending CA3136369A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
CA3136369A1 true CA3136369A1 (en) 2020-10-22

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136369A Pending CA3136369A1 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Country Status (9)

Country Link
US (2) US11643429B2 (https=)
EP (1) EP3955937A4 (https=)
JP (1) JP2022529315A (https=)
KR (1) KR20210154214A (https=)
CN (1) CN114007625A (https=)
AU (1) AU2020259997B2 (https=)
CA (1) CA3136369A1 (https=)
IL (1) IL287280A (https=)
WO (1) WO2020212760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP7700045B2 (ja) 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
IL302173A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4419502A4 (en) * 2021-10-20 2025-10-29 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
WO2024134266A1 (en) * 2022-12-20 2024-06-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
RU2263117C2 (ru) * 2001-04-27 2005-10-27 Пфайзер Продактс Инк. Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
WO2010086350A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9-deoxo- 9a-methyl- 9a- aza- 9a-h0m0erythr0mycin a derivatives for the treatment of neutrophil dominated inflammatory diseases
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
CA2840626A1 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
AU2013239679A1 (en) * 2012-03-27 2014-10-30 Michael W. BURNET Anti-inflammatory macrolides
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
JP2019513775A (ja) 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
EP3600272A4 (en) 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES

Also Published As

Publication number Publication date
IL287280A (en) 2021-12-01
EP3955937A4 (en) 2023-01-18
JP2022529315A (ja) 2022-06-21
WO2020212760A2 (en) 2020-10-22
KR20210154214A (ko) 2021-12-20
AU2020259997B2 (en) 2025-08-07
AU2020259997A1 (en) 2021-11-25
US20230348517A1 (en) 2023-11-02
US11643429B2 (en) 2023-05-09
US20210230205A1 (en) 2021-07-29
WO2020212760A3 (en) 2021-02-25
CN114007625A (zh) 2022-02-01
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
US11643429B2 (en) Compounds and methods for the treatment of ocular disorders
US11634411B2 (en) Compounds and methods for the treatment of ocular disorders
AU2021363702A9 (en) Compounds and methods for the treatment of ocular disorders
AU2020259996B2 (en) Compounds and methods for the treatment of ocular disorders
EP4232458A1 (en) Compounds and methods for the treatment of ocular disorders
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
CA3196146A1 (en) Compounds and methods for the treatment of ocular disorders
HK40068817A (en) Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240416

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250327

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250507

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251103

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251103